drugset / Trial / NCT00946920

A Trial of Degarelix in Patients With Prostate Cancer

NCT00946920

Phase 3 Completed 859 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

A phase 3, open-label, parallel group, one year trial comparing the efficacy and safety of degarelix 3-month depot with the established therapy goserelin acetate 3-month implant in patients with prostate cancer.

Timeline

Start
2009-06
Primary completion
2011-03
Completion
2011-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified 480 mg Subcutaneous
Comparator Goserelin Other / unclassified 10.8 mg Subcutaneous

Indications